Dozens of mucosal COVID-19 vaccines are in development (see ‘High hopes’) and several have been approved in countries including China and India. But according to an 8 December report by the London-based data and analytics firm Airfinity, the efficacy of existing mucosal COVID-19 vaccines has been disappointing and the available data suggest that “they do not offer a meaningful increase in protection against infection”.
Source: Airfinity
However, the latest studies in monkeys and other laboratory animals offer hints on how these vaccines might be improved. A team led by Dan Barouch, a vaccine scientist at Beth Israel Deaconess Medical Center in Boston, Massachusetts, tried two approaches in monkeys that had previously received COVID-19 jabs: squirting a liquid vaccine into the animals’ noses, or applying it directly to their tracheae1.
Only the trachea-delivered vaccine substantially boosted mucosal immunity and protection against SARS-CoV-2 infection. “We think that the problem with intranasal delivery is that most of the vaccine is either swallowed or sneezed out,” Barouch says. The results were published in Nature on 14 December. Read Full Article…
https://cvvr.hms.harvard.edu/wp-content/uploads/2020/12/nature.jpg400400Sesedzayi Persesuhhttps://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.pngSesedzayi Persesuh2023-12-22 10:41:452023-12-22 10:41:45Inhaled COVID vaccines stop infection in its tracks in monkey trials
